Effect of NXY‐059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window

• Published in: British journal of pharmacology 2002-01, Vol.135 (1), p.103-112
• Main Authors: Sydserff, S G, Borelli, A R, Green, A R, Cross, A J
• Format: Article
• Language: English
• Subjects: Administration, Cutaneous; Animals; Benzenesulfonates; Biological and medical sciences; Brain Ischemia - drug therapy; Brain Ischemia - pathology; Brain Ischemia - physiopathology; Cerebral Cortex - drug effects; Cerebral Cortex - pathology; Cerebral Cortex - physiopathology; Cerebral Infarction - drug therapy; Cerebral Infarction - pathology; Cerebral Infarction - physiopathology; Cerebrovascular Circulation - drug effects; Cerebrovascular Circulation - physiology; Disease Models, Animal; Dose-Response Relationship, Drug; Infarction, Middle Cerebral Artery - physiopathology; Infusion Pumps, Implantable; Ischemic Attack, Transient - drug therapy; Ischemic Attack, Transient - pathology; Ischemic Attack, Transient - physiopathology; Male; Medical sciences; Neuropharmacology; Neuroprotective agent; Neuroprotective Agents - blood; Neuroprotective Agents - pharmacokinetics; Neuroprotective Agents - therapeutic use; Nitrogen Oxides - blood; Nitrogen Oxides - pharmacokinetics; Nitrogen Oxides - therapeutic use; nitrone; NXY‐059; permanent cerebral ischaemia; Pharmacology. Drug treatments; radical trapping agent; Rats; Rats, Inbred WKY; Stroke; therapeutic window; transient cerebral ischaemia
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1038/sj.bjp.0704449

The efficacy of the free radical trapping agent NXY‐059 in reducing the infarct volume following both transient and permanent focal ischaemia has been examined in rats. In the transient ischaemia model, rats were subjected to a 2 h occlusion of the middle cerebral artery (MCA). Intravenous infusion of NXY‐059 (1, 10 and 30 mg kg−1 h) for 21.75 h starting 2.25 h after the occlusion, produced a dose‐dependent decrease in both neurological impairment and the histologically measured infarct volume (a mean 59% decrease at 10 mg kg−1 h). In the permanent ischaemia model, animals were injected (s.c.) with a loading dose of NXY‐059 of 32.5, 53.8 or 75.4 mg kg−1 and osmotic minipumps were implanted which had been primed to deliver respectively 30, 50 or 70 mg kg−1 h. When treatment was initiated 5 min after MCA occlusion there was a dose dependent protection of both cortical and sub‐cortical tissue (cortex: 63% at the mid‐range dose). Protection was related linearly to plasma concentration (plasma unbound NXY‐059 concentration at 1 h: 37±16 μmol l−1 at the mid‐range dose). When the mid range dose was administered between 5 min – 4 h after MCA occlusion, a marked and statistically significant protection was seen at all time points (44% protection in cortex at 4 h). These data demonstrate the substantial neuroprotective efficacy of NXY‐059 at plasma concentrations that can be achieved clinically and indicate that NXY‐059 also has a therapeutic window of opportunity that is clinically relevant. British Journal of Pharmacology (2002) 135, 103–112; doi:10.1038/sj.bjp.0704449